Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

In the fight against leukemia, even the most advanced treatments carry a significant risk of the disease returning. Now, Chinese scientists have developed a kind of "double-sided tape" that helps the ...

Chinese scientists have improved upon an existing powerful leukemia treatment, which now works even when cancer cells try to ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

She thought it was a case of the flu. As the weeks passed, the Pilates instructor's symptoms worsened. Weiss could no longer ...

Acute myeloid leukemia, often called AML, is one of the most aggressive forms of blood cancer. It develops in the bone marrow, the soft tissue inside bones where blood cells are made. In healthy ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

Researchers will test the cell therapy in a dozen patients with CD19-expressing blood cancers, including diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia.